Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification

European Respiratory Journal

Volumn 38, Issue 2, 2011, Pages 239-243

  Travis, W D ^a   Brambilla, E ^b   Van Schil, P ^c   Scagliotti, G V ^f   Huber, R M ^g   Sculier, J P ^d   Vansteenkiste, J ^e   Nicholson, A G ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HÔPITAL MICHALLON   (France)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF MUNICH   (Germany)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CLASSIFICATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; EGFR GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL SOCIETY; MICROSCOPY; PRIORITY JOURNAL;

ADENOCARCINOMA; BIOPSY; HUMANS; LUNG NEOPLASMS;

EID: 80051562838     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00026711     Document Type: Editorial

References (30)

1. Travis WD, Brambilla E, Noguchi M, et al. The New IASLC/ATS/ERS International Multidisciplinary Lung Adenocarcinoma Classification. J Thoracic Oncol 2011; 6: 244-285.
2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patientswith non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
5. Zhou C, Wu Y-L, Chen G, et al. Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 2010; 21: LBA 13.
6. Travis WD, Brambilla E, Müller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC, 2004.
7. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumors. Third Edn. Berlin, Springer, 1999.
8. World Health Organization. Histological Typing of Lung Tumours. First Edn. Geneva, World Health Organization, 1967.
9. World Health Organization. Histological Typing of Lung Tumours. Second Edn. Geneva, World Health Organization, 1981.
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191. (Pubitemid 41095154)
11. Syrigos KN, Vansteenkiste J, Parikh P, et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol 2010; 21: 556-561.
12. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1420.
13. Scagliotti GV, Parikh P, von PJ, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
14. Foot NC. The identification of types of pulmonary cancer in cytologic smears. Am J Pathol 1952; 28: 963-983.
15. Johnston WW. Cytologic diagnosis of lung cancer. Principles and problems. Pathol Res Pract 1986; 181: 1-36. (Pubitemid 16105818)
16. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010; 5: 411-414.
17. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009; 4: 1202-1211.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 28, 363: 1693-1703.
19. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008; 10: 242-248. (Pubitemid 351692167)
20. Lim EH, Zhang SL, Li JL, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2009; 4: 12-21.
21. Solomon SB, Zakowski MF, Pao W, et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010; 194: 266-269.
22. Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol 2009; 27: e141-e142.
23. Van Schil PE, Asamura H, Rusch V, et al. Surgical implications of the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011; submitted.
24. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009; 15: 6790-6799.
25. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009; 33: 1752-1764.
26. Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol 2010; 5: 197-205.
27. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on the analysis of 514 stage I cases. Mod Pathol 2011; 24: 653-664.
28. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol 2009; 33: 462-469.
29. Bhure UN, Lardinois D, Kalff V, et al. Accuracy of CT parameters for assessment of tumour size and aggressiveness in lung adenocarcinoma with bronchoalveolar elements. Br J Radiol 2010; 83: 841-849.
30. Lee HY, Han J, Lee KS, et al. Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 2009; 66: 379-385.